IPFsym™

State of the Art QSP Software for Idiopathic Pulmonary Fibrosis (IPF)

Harness the predictive power for IPF:

Representation of key IPF elements:

- lung fibrosis
- alveolar epithelial injury
- inflammation
- lung function tests
- disease progression
- lung imaging assessments

Includes IPF population (SimPops®) of greater than 700 patients with inter-patient variability in pathophysiology, disease progression, and respiratory function

Support IPF drug development

- Combines PK, PD, MoA, and disease pathophysiology to predict efficacy of novel treatments

- Predict efficacy for compounds as monotherapies and in combination with the standards of care for IPF patients, nintedanib and pirfenidone

- Optimize clinical trial protocols by identifying optimal dosing paradigms, sampling frequencies, patient inclusion/exclusion criteria, and more

- Use simulations to identify key hypotheses related to mechanistic underpinnings of predicted response to treatment



SimulationsPlus

www.DILIsym.com +1-919-558-1323 simulations-plus.com/ipfsym

Connect with us:

Rev. 04/27/2021